Africa Fights Sickle Cell With New Local Drug

A Senegalese pharmaceutical firm, Teranga Pharma, has commenced the production of Drepaf, a generic hydroxyurea treatment for sickle cell disease. This marks the first instance of such essential medication being manufactured locally in Africa. The drug, available in adult and pediatric doses, is designed to be more affordable and accessible than imported alternatives.

This development is crucial as Africa bears a significant burden of sickle cell cases, yet remains heavily reliant on costly imported treatments. Supply chain disruptions have frequently impacted the availability of imported hydroxyurea, affecting 78 percent of healthcare professionals surveyed in 13 sub-Saharan African countries.

Teranga Pharma's Drepaf is priced competitively, costing up to three times less than existing imported brands like Hydrea and Siklos. The company, working with an Indian technical partner, aims to boost production and extend its reach to other African nations, with Burkina Faso, Guinea, and Ivory Coast already engaged.

The initiative is a significant stride towards pharmaceutical sovereignty for Africa, with a goal to meet the demand across the sub-Saharan continent by 2030. Patient testimonials highlight the positive impact of Drepaf, with improvements noted in managing disease episodes and fewer required doses compared to previous treatments.